From Nasdaq: 2025-05-20 22:03:00

Johnson & Johnson’s DARZALEX FASPRO gets positive vote from FDA committee for high-risk smoldering multiple myeloma treatment. The application was submitted in November 2024. The committee reviewed data from the AQUILA study. The ODAC makes non-binding recommendations, with final decisions made by the FDA. Visit rttnews.com for more health news.



Read more at Nasdaq: FDA Panel Votes In Favor Of J&J’ DARZALEX FASPRO For High-Risk Smoldering Multiple Myeloma Treatment